Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 1801 AL 1815

Nose-to-brain drug delivery for the treatment of Alzheimer's disease: current advancements and challenges

A P, Agrawal M, Dethe MR, Ahmed H, Yadav A, Gupta U, Alexander A.

Expert Opin Drug Deliv. 2022 Jan;19(1):87-102. doi: 10.1080/17425247.2022.2029845. Epub 2022 Jan 28.

Marine Organisms as Alkaloid Biosynthesizers of Potential Anti-Alzheimer Agents

Lima E, Medeiros J.

Mar Drugs. 2022 Jan 15;20(1):75. doi: 10.3390/md20010075.

Post-Ischemic Brain Neurodegeneration in the Form of Alzheimer's Disease Proteinopathy: Possible Therapeutic Role of Curcumin

Pluta R, Furmaga-Jabłońska W, Januszewski S, Czuczwar SJ.

Nutrients. 2022 Jan 7;14(2):248. doi: 10.3390/nu14020248.

Potential of flavonoids as anti-Alzheimer's agents: bench to bedside

Kaur R, Sood A, Lang DK, Bhatia S, Al-Harrasi A, Aleya L, Behl T.

Environ Sci Pollut Res Int. 2022 Apr;29(18):26063-26077. doi: 10.1007/s11356-021-18165-z. Epub 2022 Jan 24.

Progress in the development of naturally derived active metabolites-based drugs: Potential therapeutics for Alzheimer's disease

Mani R, Sha Sulthana A, Muthusamy G, Elangovan N.

Biotechnol Appl Biochem. 2022 Dec;69(6):2713-2732. doi: 10.1002/bab.2317. Epub 2022 Feb 8.

A New Perspective on the Treatment of Alzheimer's Disease and Sleep Deprivation-Related Consequences: Can Curcumin Help?

Küpeli Akkol E, Bardakcı H, Yücel Ç, Şeker Karatoprak G, Karpuz B, Khan H.

Oxid Med Cell Longev. 2022 Jan 12;2022:6168199. doi: 10.1155/2022/6168199. eCollection 2022.

Recent Insights on Glutamatergic Dysfunction in Alzheimer's Disease and Therapeutic Implications

Pinky PD, Pfitzer JC, Senfeld J, Hong H, Bhattacharya S, Suppiramaniam V, Qureshi I, Reed MN.

Neuroscientist. 2023 Aug;29(4):461-471. doi: 10.1177/10738584211069897. Epub 2022 Jan 25.

Regulation of microRNAs in Alzheimer´s disease, type 2 diabetes, and aerobic exercise training

De Sousa RAL, Improta-Caria AC.

Metab Brain Dis. 2022 Mar;37(3):559-580. doi: 10.1007/s11011-022-00903-y. Epub 2022 Jan 25.

Exploring the dual character of metformin in Alzheimer's disease

Ning P, Luo A, Mu X, Xu Y, Li T.

Neuropharmacology. 2022 Apr 1;207:108966. doi: 10.1016/j.neuropharm.2022.108966. Epub 2022 Jan 22.

Tau protein aggregation: Key features to improve drug discovery screening

Giovannini J, Smeralda W, Jouanne M, Sopkova-de Oliveira Santos J, Catto M, Voisin-Chiret AS.

Drug Discov Today. 2022 May;27(5):1284-1297. doi: 10.1016/j.drudis.2022.01.009. Epub 2022 Jan 24.

Advances in prodrug design for Alzheimer's disease: the state of the art

Travers-Lesage V, Mignani SM, Dallemagne P, Rochais C.

Expert Opin Drug Discov. 2022 Apr;17(4):325-341. doi: 10.1080/17460441.2022.2031972. Epub 2022 Feb 23.

Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential

Gao L, Zhang Y, Sterling K, Song W.

Transl Neurodegener. 2022 Jan 28;11(1):4. doi: 10.1186/s40035-022-00279-0.

Alzheimer's disease therapy based on acetylcholinesterase inhibitor/blocker effects on voltage-gated potassium channels

Li XT.

Metab Brain Dis. 2022 Mar;37(3):581-587. doi: 10.1007/s11011-022-00921-w. Epub 2022 Jan 31.

Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer's disease: a systematic review and meta-analysis

Wang H, Zong Y, Han Y, Zhao J, Liu H, Liu Y.

Expert Opin Drug Saf. 2022 Mar;21(3):407-415. doi: 10.1080/14740338.2022.2027905. Epub 2022 Jan 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias